Ligand Pharmaceuticals Incorporated (LGND) stock surged +3.00%, trading at $116.91 on NASDAQ, up from the previous close of $113.51. The stock opened at $113.70, fluctuating between $113.59 and $117.28 in the recent session.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Employees | 58 |
Beta | 0.9 |
Sales or Revenue | $131.31M |
5Y Sales Change% | -0.274% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) stock price is $116.91 in the last trading session. During the trading session, LGND stock reached the peak price of $117.28 while $113.59 was the lowest point it dropped to. The percentage change in LGND stock occurred in the recent session was 3% while the dollar amount for the price change in LGND stock was $3.40.
The NASDAQ listed LGND is part of Biotechnology industry that operates in the broader Healthcare sector. Ligand Pharmaceuticals Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Audrey Warfield-Graham
Chief People Officer
Mr. Todd Pettingill
Director of Corporation Devel.
Mr. Matthew E. Korenberg
Pres & Chief Operating Officer
Dr. Vincent D. Antle
Senior Vice President of Technical Operations & QA - Capitsol
Mr. Todd C. Davis
Chief Executive Officer & Director
Mr. John L. Higgins
Executive Director
Simon Latimer
Head of Investor Relations
Dr. Keith Marschke
Senior Vice President of Biology & Scientific Affairs
Mr. Octavio Espinoza
Chief Financial Officer
Mr. Patrick Lucy
Senior Vice President & CBO Protein Expression Bus.
Mr. Andrew T. Reardon J.D.
Chief Legal Officer & Sec.
Mr. Todd C. Davis Ph.D.
Chief Executive Officer & Director
LGND's closing price is 77.57% higher than its 52-week low of $65.84 where as its distance from 52-week high of $129.90 is -10%.
Number of LGND employees currently stands at 58.
Official Website of LGND is: https://www.ligand.com
LGND could be contacted at phone 858 550 7500 and can also be accessed through its website. LGND operates from 5980 Horton Street, EmeryVille, CA 94608, United States.
LGND stock volume for the day was 107.19K shares. The average number of LGND shares traded daily for last 3 months was 113.2K.
The market value of LGND currently stands at $2.21B with its latest stock price at $116.91 and 18.9M of its shares outstanding.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com